Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176800 · ClinicalTrials.gov registry record · Phase 2
Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT00176800 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 69 participants.
The verdict
NCT00176800, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
Surgery has been the standard of care for esophageal cancer for many years, with limited success. At present, several studies are underway nationwide which utilize chemotherapy combined with radiation therapy prior to the usual surgical regimen. Although this treatment offers some possibility for improvement of patients with esophageal cancer, there remains a significant need for development of new drugs that can substantially impact survival Investigators at the University of Michigan have been evaluating inhibitors of tumor blood vessel growth (angiogenesis). Specifically, they are evaluating the role of copper in angiogenesis. Copper has been shown to be both a requirement and a potent stimulus for angiogenesis. Previous studies have shown Tetrathiomolybdate (TM) to rapidly lower copper levels in the blood. The physicians at the University of Michigan are studying whether the addition of TM to the chemoradiation and surgery may increase survival for patients with esophageal cancer.
Interventions
- PROCEDURE Surgery
- PROCEDURE Radiation
- DRUG Tetrathiomolybdate (TM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2001-11 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176800
The ClinicalTrials.gov registry entry for NCT00176800 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Surgery is the first listed.
NCT00176800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00176800 about?
NCT00176800 is a clinical study titled "Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma". Surgery has been the standard of care for esophageal cancer for many years, with limited success. At present, several studies are underway nationwide which utilize chemotherapy combined with radiation therapy prior to the usual surgical regimen. Although this treatment offers some possibility for im...
What is the current status of trial NCT00176800?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2001-11. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00176800?
The interventions under investigation include: Surgery (PROCEDURE), Radiation (PROCEDURE), Tetrathiomolybdate (TM) (DRUG).
Who is sponsoring clinical trial NCT00176800?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.